PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › SKY-0515

Drugs in development · updated 30 October 2026

SKY-0515: clinical trials and development status

Development codeNot approved in the USNo EMA authorisationEstimated launch Jul 2028 – May 2029 (Phuturdex estimate)

As of 30 October 2026 SKY-0515 is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 2 diseases. The most advanced phase is II–III.

3Active trials
II–IIIMost advanced phase
2Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow SKY-0515 and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Huntington's diseaseII–III3NCT07378644
ChoreaII–III1NCT06873334

Everything on SKY-0515

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch